货号 (SKU)

包装规格

是否现货

价格

数量

Ab176574-100μg

100μg

现货

Ab176574-1mg

1mg

现货

Ab176574-5mg

5mg

现货

Ab176574-10mg

10mg

期货

基本信息

产品名称	Garadacimab (anti-Factor XII)
别名	加达西单抗 \| 加拉昔单抗(抗因子 XII)
英文别名	Factor XII antibody \| Beta factor XIIa part 1 antibody \| Beta factor XIIa part 2 antibody \| Coagulation factor XII antibody \| Coagulation factor XIIa heavy chain antibody \| Coagulation factor XIIa light chain antibody \| F12 antibody \| F12 deficiency antib
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	F12
种属反应性	人(Human),小鼠(Mouse)
偶联	Unconjugated

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	lambdaC2
SDS-PAGE	27.5 kDa (Light Chain) & 52.5 kDa (Heavy Chain), under reducing conditions; 191.9 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
储存缓冲液	Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	2162134-62-3
分子类型	抗体

图片

SEC: Garadacimab (anti-Factor XII) (Ab176574)

Garadacimab (anti-Factor XII) (Ab176574) - SEC
The purity of Garadacimab (anti-Factor XII) (Ab176574) is more than 95% verified by HPLC.

关联靶点（人）

F12 Tchem 凝血因子 XII(Coagulation factor XII) (0 活性数据)

点击查看靶蛋白信息： F12

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

安全和危险性（GHS）

SDS英文版

质量标准

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到3个结果

批号(Lot Number)	证书类型	日期	货号
ZJ24F0404322	分析证书	24-04-10	Ab176574
ZJ24F0404321	分析证书	24-04-10	Ab176574
ZJ24F0404320	分析证书	24-04-10	Ab176574

参考文献

1. D X Beringer,L M J Kroon-Batenburg. (2013-02-07) The structure of the FnI-EGF-like tandem domain of coagulation factor XII solved using SIRAS.. Acta crystallographica. Section F, Structural biology and crystallization communications, 69 ((Pt 2)): (94-102). [PMID:23385745]
2. Sidhu PS, Mosier PD, Zhou Q, Desai UR.. (2013) On scaffold hopping: challenges in the discovery of sulfated small molecules as mimetics of glycosaminoglycans.. Bioorg Med Chem Lett, 23 (1): (355-359). [PMID:23164711] [10.1016/j.bmcl.2012.10.079]
3. Al-Horani RA, Ponnusamy P, Mehta AY, Gailani D, Desai UR.. (2013) Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa.. J Med Chem, 56 (3): (867-878). [PMID:23316863] [10.1021/jm301338q]
4. Zhang X, Glunz PW, Johnson JA, Jiang W, Jacutin-Porte S, Ladziata V, Zou Y, Phillips MS, Wurtz NR, Parkhurst B, Rendina AR, Harper TM, Cheney DL, Luettgen JM, Wong PC, Seiffert D, Wexler RR, Priestley ES.. (2016) Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex.. J Med Chem, 59 (15): (7125-7137). [PMID:27455395] [10.1021/acs.jmedchem.6b00469]
5. Middendorp SJ, Wilbs J, Quarroz C, Calzavarini S, Angelillo-Scherrer A, Heinis C.. (2017) Peptide Macrocycle Inhibitor of Coagulation Factor XII with Subnanomolar Affinity and High Target Selectivity.. J Med Chem, 60 (3): (1151-1158). [PMID:28045547] [10.1021/acs.jmedchem.6b01548]
6. Chen P, Zhang D, Li M, Wu Q, Lam YPY, Guo Y, Chen C, Bai N, Malhotra S, Li W, O'Connor PB, Fu H.. (2019) Discovery of novel, potent, isosteviol-based antithrombotic agents.. Eur J Med Chem, 183 (111722-111722). [PMID:31563807] [10.1016/j.ejmech.2019.111722]
7. Swedberg JE, Ghani HA, Harris JM, de Veer SJ, Craik DJ.. (2018) Potent, Selective, and Cell-Penetrating Inhibitors of Kallikrein-Related Peptidase 4 Based on the Cyclic Peptide MCoTI-II.. ACS Med Chem Lett, 9 (12): (1258-1262). [PMID:30613336] [10.1021/acsmedchemlett.8b00422]
8. Davoine C,Bouckaert C,Fillet M,Pochet L. (2020) Factor XII/XIIa inhibitors: Their discovery, development, and potential indications.. Eur J Med Chem, 208 (112753-112753). [PMID:32883641] [10.1016/j.ejmech.2020.112753]
9. Harris, R J RJ, Ling, V T VT and Spellman, M W MW.. (1992) O-linked fucose is present in the first epidermal growth factor domain of factor XII but not protein C.. The Journal of biological chemistry, (15): [PMID:1544894]
10. Miyata, T T and 5 more authors.. (1989) Coagulation factor XII (Hageman factor) Washington D.C.: inactive factor XIIa results from Cys-571----Ser substitution.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2510163]
11. Bernardi, F F and 9 more authors.. (1987) Factor XII gene alteration in Hageman trait detected by TaqI restriction enzyme.. Blood, [PMID:2882793]
12. Cool, D E DE and MacGillivray, R T RT.. (1987) Characterization of the human blood coagulation factor XII gene. Intron/exon gene organization and analysis of the 5'-flanking region.. The Journal of biological chemistry, (5): [PMID:2888762]
13. Que, B G BG and Davie, E W EW.. (1986) Characterization of a cDNA coding for human factor XII (Hageman factor).. Biochemistry, (8): [PMID:3011063]
14. Tripodi, M M and 5 more authors.. (1986) cDNA sequence coding for human coagulation factor XII (Hageman).. Nucleic acids research, (11): [PMID:3754331]
15. Cool, D E DE and 5 more authors.. (1985) Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XIIa.. The Journal of biological chemistry, (5): [PMID:3877053]
16. McMullen, B A BA and Fujikawa, K K.. (1985) Amino acid sequence of the heavy chain of human alpha-factor XIIa (activated Hageman factor).. The Journal of biological chemistry, (10): [PMID:3886654]
17. Fujikawa, K K and McMullen, B A BA.. (1983) Amino acid sequence of human beta-factor XIIa.. The Journal of biological chemistry, (25): [PMID:6604055]
18. de Agostini, A A, Lijnen, H R HR, Pixley, R A RA, Colman, R W RW and Schapira, M M.. (1984) Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.. The Journal of clinical investigation, [PMID:6725552]
19. Hovinga, J K JK and 5 more authors.. (1994) Coagulation factor XII Locarno: the functional defect is caused by the amino acid substitution Arg 353-->Pro leading to loss of a kallikrein cleavage site.. Blood, (15): [PMID:8049433]
20. Schloesser, M M and 5 more authors.. (1995) The novel acceptor splice site mutation 11396(G-->A) in the factor XII gene causes a truncated transcript in cross-reacting material negative patients.. Human molecular genetics, [PMID:8528215]
21. Schloesser, M M and 11 more authors.. (1997) Mutations in the human factor XII gene.. Blood, (15): [PMID:9354665]
22. Kondo, S S and 5 more authors.. (1999) Factor XII Tenri, a novel cross-reacting material negative factor XII deficiency, occurs through a proteasome-mediated degradation.. Blood, (15): [PMID:10361128]
23. Bencharit, Sompop S and 6 more authors.. (2003) Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition.. Chemistry & biology, [PMID:12725862]
24. Bunkenborg, Jakob J, Pilch, Bartosz J BJ, Podtelejnikov, Alexandre V AV and Wiśniewski, Jacek R JR.. (2004) Screening for N-glycosylated proteins by liquid chromatography mass spectrometry.. Proteomics, [PMID:14760718]
25. Ishii, Keiko K and 7 more authors.. (2004) Genetic analyses and expression studies identified a novel mutation (W486C) as a molecular basis of congenital coagulation factor XII deficiency.. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, [PMID:15205584]
26. Oguchi, Shuji S and 6 more authors.. (2005) Factor XII Shizuoka, a novel mutation (Ala392Thr) identified and characterized in a patient with congenital coagulation factor XII deficiency.. Thrombosis research, [PMID:15617741]
27. Liu, Tao T and 6 more authors.. Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.. Journal of proteome research, [PMID:16335952]
28. Dewald, Georg G and Bork, Konrad K.. (2006) Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor.. Biochemical and biophysical research communications, (19): [PMID:16638441]
29. Cichon, Sven S and 11 more authors.. (2006) Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III.. American journal of human genetics, [PMID:17186468]
30. MacQuarrie, Jessica L JL and 6 more authors.. (2011) Histidine-rich glycoprotein binds factor XIIa with high affinity and inhibits contact-initiated coagulation.. Blood, (14): [PMID:21304106]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Garadacimab (anti-Factor XII)

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器

Garadacimab (anti-Factor XII)

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器